全文获取类型
收费全文 | 6758篇 |
免费 | 402篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 223篇 |
妇产科学 | 65篇 |
基础医学 | 1166篇 |
口腔科学 | 281篇 |
临床医学 | 558篇 |
内科学 | 1024篇 |
皮肤病学 | 239篇 |
神经病学 | 794篇 |
特种医学 | 270篇 |
外科学 | 865篇 |
综合类 | 37篇 |
一般理论 | 2篇 |
预防医学 | 262篇 |
眼科学 | 291篇 |
药学 | 545篇 |
中国医学 | 9篇 |
肿瘤学 | 488篇 |
出版年
2023年 | 19篇 |
2022年 | 51篇 |
2021年 | 97篇 |
2020年 | 83篇 |
2019年 | 69篇 |
2018年 | 110篇 |
2017年 | 99篇 |
2016年 | 135篇 |
2015年 | 181篇 |
2014年 | 195篇 |
2013年 | 248篇 |
2012年 | 373篇 |
2011年 | 376篇 |
2010年 | 268篇 |
2009年 | 266篇 |
2008年 | 484篇 |
2007年 | 415篇 |
2006年 | 427篇 |
2005年 | 426篇 |
2004年 | 467篇 |
2003年 | 421篇 |
2002年 | 395篇 |
2001年 | 126篇 |
2000年 | 110篇 |
1999年 | 108篇 |
1998年 | 101篇 |
1997年 | 99篇 |
1996年 | 73篇 |
1995年 | 57篇 |
1994年 | 48篇 |
1993年 | 49篇 |
1992年 | 47篇 |
1991年 | 33篇 |
1990年 | 38篇 |
1989年 | 56篇 |
1988年 | 41篇 |
1987年 | 33篇 |
1986年 | 26篇 |
1985年 | 29篇 |
1984年 | 21篇 |
1983年 | 18篇 |
1982年 | 29篇 |
1981年 | 19篇 |
1980年 | 19篇 |
1979年 | 21篇 |
1978年 | 19篇 |
1977年 | 20篇 |
1974年 | 18篇 |
1973年 | 22篇 |
1972年 | 19篇 |
排序方式: 共有7181条查询结果,搜索用时 31 毫秒
101.
Root cultures of COLEUS FORSKOHLII Briq. were initiated from primary callus or IBA-treated suspension cultures and maintained on Gamborg's B5 medium containing 1 mg/l IBA. Transformed root cultures were established by infecting surface-sterilized leaves with AGROBACTERIUM RHIZOGENES strain 15834. Transformation was confirmed by mannopine detection. These cultures displayed the typical characteristics of hairy root cultures, with the sole exceptions of slow growth in hormone-free medium and accelerated growth on medium containing phytohormones. All root cultures examined formed forskolin and its derivatives in amounts ranging from 500 to 1300 mg/kg dry weight, corresponding to about 4 to 5 mg/l. During cultivation roots could be cut into small pieces without affecting growth and forskolin production. Scale-ups of the cultivation procedure were performed in 20-l glass jars with a working volume of 10 to 13l. Forskolin production in bioreactors was better than in shake flasks. Levels of almost 14 mg/l could be reached after 21 d of cultivation. As in the shake flask experiments cutting the roots did not affect growth or productivity in a negative way. 相似文献
102.
Reinhard Wölfel Karl-Heinz Graefe 《Naunyn-Schmiedeberg's archives of pharmacology》1992,345(2):129-136
Summary The aim of the present study was to answer the question whether amines other than 5-hydroxytryptamine (5-HT) and tryptamine act as substrates of the platelet 5-HT transporter. To this end, a large number of tryptamines, 5-HT receptor agonists and phenethylamines (which had IC50 values for 3H-5-HT uptake inhibition of 145–24500 nmol l–1) was examined in rabbit platelets in order to determine their ability to induce an outward transport of 3H-5-HT Platelets (the MAO of which was blocked) from reserpine-pretreated animals were loaded with 3H-5-HT and then exposed for 5 min to various concentrations (ranging from 0.25 to 40 times the IC50) of each compound. The concentration-effect curves for the drug-induced increase in 3H-5-HT efflux served to determine values of Emax (maximum increase in efflux expressed in % of the 3H-5-HT content of cells) and EC50 (drug concentration producing Emax/2).For the 24 compounds studied here (which included the 5-HT uptake inhibitors imipramine, citalopram, fluoxetine and cocaine) a linear correlation between EC50 and IC50 (r = 0.975) and a mean ratio of EC50/IC50 of 2.4 was found. Most of the compounds [e.g., (±)8-hy-ydroxy-2-(N,N-dipropylamino)tetralin, S(+)-methyl-5-HT, 5-carboxamidotryptamine and 5-methoxytryptamine] gave rise to Emax values (15.8–32.5%) that exceeded that brought about by imipramine (6.6%), indicating that they act as substrates of the 5-HT transporter; the 3H-5-HT outward transport observed in response to these substances was abolished in the presence of imipramine. Others (e.g., 2-methyl-5-HT and 5-methylurapidil) produced Emax values (3.4–14.3%) not significantly different from that of imipramine and, therefore, can be classified either as poor substrates or as inhibitors of the 5-HT transporter.Hence, many tryptamines and 5-HT receptor agonists are substrates of the platelet 5-HT transporter. The property of being substrates gives them the latent capacity to bring about release of endogenous 5-HT and, as a result, to cause indirect 5-HT receptor-mediated effects.Abbreviations MAO
monoamine oxidase
- 5-HT
5-hydroxytryptamine
- 2-M-5-HT
2-methyl-5-HT
- N-M-5-HT
N-methyl-5-HT
- N,N-DM-5-HT
N,N-dimethyl-5-HT
- S(+)-M-5-HT
S(+)-methyl-5-HT
- 5-CT
5-carboxamidotryptamine
- 5-M-tryptamine
5-methyltryptamine
- 5-MO-tryptamine
5-methoxytryptamine
- 7-M-tryptamine
7-methyltryptamine
- N-M-tryptamine
N-methyltryptamine
- N,N-DM-tryptamine
N,N-dimethyltryptamine
- N,N-DM-5-MO-tryptamine
N,N-dimethyl-5-methoxytryptamine
- (±)8-OH-DPAT
(±)8-hydroxy-2-2-(N,N-dipropylamino)tetralin
- 5-M-urapidil
5-methyl-urapidil
Send offprint requests to R. Wölfel at the above address 相似文献
103.
104.
The release profiles of intact and enzymatically digested hyaluronic acid from semisolid formulations using multi-layer membrane system. 总被引:2,自引:0,他引:2
Jamal Alyoussef Alkrad Yahya Mrestani Reinhard H H Neubert 《European journal of pharmaceutics and biopharmaceutics》2003,56(1):37-41
A multi-layer membrane system was used to measure in vitro release of hydrophilic macromolecules such as hyaluronic acid (HA) from semisolid formulations. One enzymatically digested HA-derivative with molecular mass of 22 kDa (HA-D) and 1200 kDa intact HA (HA) were incorporated into three semisolid formulations: water-containing hydrophilic ointment (WHO), amphiphilic cream (AC) and water-containing wool wax alcohol ointment (WWO). Because of the high hydrophilic properties of HA-D and HA, the artificial model membranes consisted of collodion as the matrix and glycerol as the hydrophilic acceptor phase. The area under the concentration-time curve and the mean dissolution time were used as a quantitative parameter to characterise the rate and extent of release in vitro. This study showed that the HA-D and HA release as hydrophilic substances from WHO was higher than both from AC and WWO. It was observed that 83% of HA-D1 was released from WHO after 2 h; in contrast, only 10% was released from 2% HA from the same vehicle during the same time. In conclusion, the in vitro availability of enzymatically digested HA-D was higher for WHO than for the other formulations, AC and WWO. Similarly, the availability of HA-D was higher than that of HA from the same formulations. 相似文献
105.
Thomas Martin Sandra R?ddiger Ralf Kurek Thomas Dannenberg Oliver Eckart Christos Kolotas Reinhard Heyd Bernd Rogge Dimos Baltas Ulf Tunn Nikolaos Zamboglou 《Radiotherapy and oncology》2004,71(1):35-41
PURPOSE: To evaluate treatment outcome of 3D conformal high dose rate (HDR) brachytherapy and external beam irradiation (EBRT) combined with temporary androgen deprivation for patients with localized prostate cancer. PATIENTS AND METHODS: Between January 1997 and September 1999 we treated 102 patients with stage T1-3 N0 M0 prostate cancer. Stage T1-2 was found in 71, T3 in 31 patients. Median pretreatment PSA level was 15.3 ng/ml. After ultrasound-guided transrectal implantation of four afterloading needles, CT based 3D brachytherapy planning was performed. All patients received four HDR implants using a reference dose per implant of 5 or 7Gy. Time between each implant was 14 days. After brachytherapy EBRT followed up to 39.6 or 45.0 Gy. All patients received temporary androgen deprivation, starting 2-19 months before brachytherapy, ending 3 months after EBRT. RESULTS: Median follow-up was 2.6 years (range 2.0-4.1 years). Actuarial biochemical control rate was 87% at 2 years and 82% at 3 years. In 14 patients we noted biochemical failure, in five patients clinical failure. Overall survival was 90%, disease specific survival 98.0% at 3 years. Acute grade 3 toxicity occurred in 4%, late grade 3 toxicity in 5%. One patient developed a prostatourethral-rectal fistula as late grade 4 toxicity. The conformal quality of 300 HDR implants was analyzed using dose volume histograms. CONCLUSIONS: 3D conformal HDR brachytherapy and EBRT combined with temporary androgen deprivation is an effective treatment modality for prostate cancer with minimal associated toxicity and encouraging biochemical control rates after a median follow-up of 2.6 years. 相似文献
106.
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. 总被引:14,自引:0,他引:14
Philipp Str?bel Andrea Bauer Bernhard Puppe Til Kraushaar Axel Krein Klaus Toyka Ralf Gold Michael Semik Reinhard Kiefer Wilfred Nix Berthold Schalke Hans Konrad Müller-Hermelink Alexander Marx 《Journal of clinical oncology》2004,22(8):1501-1509
PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity. This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients receiving different modes of treatment. PATIENTS AND METHODS: Two hundred twenty-eight patients were followed for up to 21 years (median, 60 months; range, 1 to 252 months) after primary surgery. Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemotherapy. RESULTS: Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years). Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radiotherapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years). Among 75 patients with B2 and B3 thymomas with incomplete resection or a tumor stage III or higher, the recurrence rate was 34% (n = 23) after 0.5 to 17 years (median, 5 years) in patients receiving adjuvant radiochemotherapy, compared to 78% (seven of nine patients) in patients without adjuvant radiochemotherapy. Incomplete tumor resection was associated with a high recurrence rate (65%) and a poor prognosis (P <.01). CONCLUSION: The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment. Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs. 相似文献
107.
Mirjana Urosevic Patrick A Oberholzer Tanja Maier Jürg Hafner Elisabeth Laine Herbert Slade Bernd Benninghoff Günter Burg Reinhard Dummer 《Clinical cancer research》2004,10(15):4959-4970
PURPOSE: Imiquimod represents a synthetic local immune response modifier that has demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha. EXPERIMENTAL DESIGN: To more closely define and elucidate mechanisms leading to basal cell carcinoma clearance in vivo, we examined gene expression profiles of skin basal cell carcinoma before and after treatment with 5% imiquimod cream (Aldara) by using high-density oligonucleotide arrays. RESULTS: We show that imiquimod predominantly induces genes involved in different aspects of immune response. In addition to effects on immunity, imiquimod treatment modulates the expression of genes involved in the control of apoptosis and oncogenesis. Array data indicated that imiquimod treatment induces expression of opioid growth factor receptor, a molecule recently reported to be a target for antitumor antibody responses. Immunohistochemistry revealed in vivo up-regulation of opioid growth factor receptor protein on tumor and on infiltrating cells after treatment. By using basal cell carcinoma cell lines treated with IFN-alpha or imiquimod, we show that opioid growth factor receptor up-regulation is IFN-alpha-mediated, rather then directly imiquimod-mediated. By using tissue microarray containing 52 basal cell carcinomas, we demonstrate opioid growth factor receptor expression in almost half of the cases. Expression of opioid growth factor receptor correlated with a longer recurrence-free period in basal cell carcinoma that recurred after radiotherapy (Kaplan-Meier analysis, P = 0.041). CONCLUSIONS: In addition to its immunomodulatory and antiproliferative activity, opioid growth factor receptor seems to have a prognostic significance in basal cell carcinoma patients. Our data add to the growing list of basal cell carcinoma-associated tumor antigens. 相似文献
108.
Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. 总被引:2,自引:0,他引:2
George A Mashour Pablo Hernáiz Driever Melanie Hartmann Stephanie N Drissel Tingguo Zhang Bianca Scharf Ursula Felderhoff-Müser Sadatoshi Sakuma Reinhard E Friedrich Robert L Martuza Victor Felix Mautner Andreas Kurtz 《Clinical cancer research》2004,10(17):5677-5683
PURPOSE: Neurofibromatosis type 1 (NF1) is characterized by systemic development of neurofibromas. Early clinical diagnosis can be ambiguous, and genetic diagnosis can be prohibitively difficult. Dysregulation of a number of growth factors has been suggested to be a mechanism of pathogenesis. This study was performed to assess the contribution of circulating growth factors for diffuse tumorigenesis and the diagnostic value of circulating growth factor identification in serum. EXPERIMENTAL DESIGN: The growth stimulation of neurofibroma-derived cells by serum from NF1 patients was tested, and serum growth factor levels in a cohort of NF1 patients (n = 39) between the ages of 7 and 70 years were analyzed. RESULTS: Concentrations of midkine (MK) and stem cell factor, but not epidermal growth factor, were substantially increased in serum of NF1 patients when compared with healthy controls. Within the NF1 group, MK levels increased dramatically at puberty from an average of 0.79 ng/mL in patients <18 years to 1.18 ng/mL in patients >18 years old. Stem cell factor and MK concentrations above a defined threshold in serum of NF1 patients are of diagnostic benefit for 96% of patients in the cohort tested. Furthermore, serum from NF1 patients enhanced proliferation of human neurofibroma-derived primary Schwann cells and endothelial cells substantially better than normal serum. CONCLUSIONS: Enhanced circulating growth factor levels contribute to diffuse tumorigenesis in NF1 and may provide the basis for molecular diagnosis. 相似文献
109.
Martin A. Graham Suresh Senan Hernani Robin Jr. Nils Eckhardt Dennis Lendrem Jeffery Hincks Dennis Greenslade Roy Rampling Stanley B. Kaye Reinhard von Roemeling Paul Workman 《Cancer chemotherapy and pharmacology》1997,40(1):1-10
Tirapazamine (3-amino-1,2,4-benzotriazine-1,4-di-N-oxide; SR 259075) is a selective hypoxic cell cytotoxic agent that is bioreductively activated in tumours to a reactive-drug
free radical. Preclinically the agent has been shown to possess additive and synergistic anti-tumour activity in combination
with radiotherapy and chemotherapy regimens. In the present study the pharmacokinetics and metabolism of tirapazamine were
investigated in mice and patients as part of pre-clinical and phase I investigations. The objectives of this work were twofold;
firstly, to evaluate retrospectively the utility of a pharmacokinetically guided dose-escalation (PGDE) strategy for tirapazamine,
and secondly, to investigate if pharmacologically relevant plasma concentrations could be achieved at tolerable doses. Pharmacokinetic
studies for PGDE were conducted in mice at four dose levels ranging from one-tenth of the LD10 to the LD50. The AUC at the LD10 (2932 μg ml-1min) was used to determine a target AUC value of 1173 μg ml-1min (equivalent to 40% of the mouse LD10 AUC) for clinical studies. A phase I study to investigate the tolerance of a single i.v. infusion of tirapazamine (once every
3 weeks) was initiated with close pharmacokinetic monitoring. The starting dose (36 mg/m2) was based on toxicity data obtained in the mouse, rat and dog. Doses were escalated by increases in the volume and duration
of infusion. A retrospective analysis of the pharmacokinetic and toxicity data was then made to determine the utility of a
PGDE approach. The drug exhibited a steep dose-lethality relationship in mice (LD10 294 mg/m2, LD50 303 mg/m2). The major gross toxicities were body-weight loss (15–20%), pilo-erection and hypoactivity at all dose levels. Sporadic
ptosis and conjunctivitis were observed at doses of >300 mg/m2. The plasma elimination of tirapazamine fitted a monoexponential open model, with rapid elimination from the plasma (t
1/2=36±0.65 min) occuring at the LD10 dose of 294 mg/m2. A 10.3-fold increase in dose resulted in a 25.0-fold increase in AUC. Clinically, doses were escalated over the range of
36–450 mg/m2. Ototoxicity (tinnitus and reversible hearing loss) was dose-limiting at 450 mg/m2 and the MTD was 390 mg/m2 for this schedule. Pharmacokinetic analyses in patients revealed that the elimination of tirapazamine in patients was generally
bi-phasic, with low inter-patient variability being found in clearance. A 12.5-fold increase in dose resulted in a 19.0-fold
increase in AUC. There was good quantitative agreement in metabolite formation between mice and humans with respect to the
two- and four-electron bioreductive metabolites. AUC values recorded for tirapazamine at the MTD of 390 mg/m2 (range 1035–1611 μg ml-1min) were similar to the target AUC in mice. Importantly, these levels are consistent with the levels required for radiation-dose
enhancement and effective combination with cisplatin in mice. Given (a) the similarities in plasma pharmacokinetics and metabolism
observed at the target AUC/MTD in mice, rats, dogs and humans, (b) the similar degree of plasma protein binding seen between
species and (c) the relatively low inter-patient variability noted in drug clearance, a successful PGDE approach should have
been feasible. The results also indicate that potentially therapeutic levels of tirapazamine are achievable in patients at
tolerable doses.
Received: 27 May 1996 / Accepted: 30 September 1996 相似文献
110.
U. Eiholzer P. Bodmer M. Bühler U. Döhmann G. Meyer P. Reinhard G. Schimert G. Varga R. Wälli R. Largo L. Molinari 《European journal of pediatrics》1998,157(7):547-552
A longitudinal growth study with monthly measurements during the 1st year of life was conducted by nine paediatricians working
in private practice in Zurich. Of 92 children, none was lost to the study and only 32 of 1104 planned visits were missed;
the quality of the measurements was comparable to that of a specialised university clinic. Compared to the Zurich Longitudinal
Growth Studies, children of this study were considerably heavier and taller. In 92% of the subjects, growth velocity was at
least once outside the reference range (3rd–97th percentile). For weight increments, the corresponding proportion was 87%.
Conclusions The data indicate that current standards for the 1st year of life for the Zurich area might no longer be appropriate and
need to be updated. The currently used velocity percentiles based on 3-monthly measurements are not suitable to assess individual
height and weight increments calculated from monthly measurements.
Received: 9 June 1997 / Accepted in revised form: 21 November 1997 相似文献